G1T48 is a proprietary, orally available, selective estrogen receptor degrader (SERD).  In preclinical studies (data presented at the American Association for Cancer Research 2017 Annual Meeting), G1T48 has been shown to be more potent than Faslodex® and to have superior anti-tumor efficacy versus other SERDs in development.  G1T48 is on track for IND filing in 4Q17.

There is strong scientific rationale and clinical validation supporting the combination of a CDK4/6 inhibitor and a SERD for the treatment of patients with estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer. G1 is planning to combine G1T38 and G1T48 as an all oral, potentially best-in-class regimen for patients with ER+, HER2- breast cancer.